With the proliferation of e-mail alerts, “chronic fatigue” takes on a whole new meaning.
You are here
P&T® Journal contents for September 2005
Dr. Goldenberg discusses ramelteon (Rozerem™) for insomnia, a lidocaine–tetracaine patch (Synera™) for local dermal analgesia, and insulin detemir (Levemir®), a short-acting insulin analogue for type-1 and type-2 diabetes.
Some new therapies include tesaglitazar for insulin-resistant nondiabetic patients; vildagliptin, exenatide, metaglidasen, insulin glargine, pioglitazone, and rimonabant for problems associated with type-2 diabetes; inhaled insulin powder for type-1 diabetes; and pregabalin for reducing pain in diabetic peripheral neuropathy.
Continuing Education Credit
The authors present an overview of some pharmacological and nonpharmacological modalities for treating the widespread public health problem of back pain, a major cause of disability in the U.S.